Skip to main content
Log in

Neuroleptic malignant syndrome during zuclopenthixol therapy in X-linked cerebral adrenoleukodystrophy

  • Published:
Journal of Inherited Metabolic Disease

Abstract

An 8 year-old boy with X-ALD under treatment with simvastatin developed a severe adverse reaction when the dose of his other medication, zuclopenthixol was increased. Both drugs were withdrawn after a diagnosis of neuroleptic malignant syndrome was made.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

REFERENCES

  • Deslypere JP, Vermeulen A (1991) Rhabdomyolysis and simvastatin. Ann Intern Med 114: 342.

    Google Scholar 

  • Gurrera RJ (1999) Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 156: 169-180.

    Google Scholar 

  • Verrips A, Willemsen MA, Rubio-Gozalbo E, De Jong J, Smeitink JA (2000) Simvastatin and plasma very-long-chain fatty acids in X-linked adrenoleukodystrophy. Ann Neurol 47: 552-553.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rubio-Gozalbo, M.E., van Waardenburg, D.A., Forget, P.P. et al. Neuroleptic malignant syndrome during zuclopenthixol therapy in X-linked cerebral adrenoleukodystrophy. J Inherit Metab Dis 24, 605–606 (2001). https://doi.org/10.1023/A:1012480130445

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1012480130445

Keywords

Navigation